A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Trispecific antibodies offer a third way forward for anticancer immunotherapy on November 18, 2019 at 8:11 am
Immunotherapy approaches seek to boost immune responses against cancer. A single antibody engineered to recognize three targets shows promise, when tested in animals, in improving the ability of T ...
- Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies on November 18, 2019 at 8:06 am
Furthermore, low-dose NanoNO reprogrammes the immunosuppressive tumour microenvironment toward an immunostimulatory phenotype, thereby improving the efficacy of cancer vaccine immunotherapy. Our ...
- How gene-edited white blood cells are helping fight cancer on November 18, 2019 at 6:04 am
So far the treatment appears safe, and more results are expected soon. Unlike chemotherapy or radiation therapy, which directly kills cancer cells, immunotherapy activates the body’s own immune system ...
- Bone Tumors Stop Immunotherapy Working For Prostate Cancer on November 16, 2019 at 9:24 am
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- Prostate cancer bone metastases thwart immunotherapy by producing TGF-beta on November 14, 2019 at 8:07 am
The discoveries by a team led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, explain why immunotherapy has been largely unsuccessful ...
- Cancer Immunotherapy Market Global Outlook by Size, Share, Trend, Growth, Demand, Industry Analysis, Business Strategies by 2023 on November 13, 2019 at 5:28 pm
Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. Get Exclusive Free Sample Copy @ ...
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapy on November 13, 2019 at 1:17 pm
Some cancer cells exploit these molecules to dial down immune attacks that would otherwise ... The 22-patient cohort was about age 67 on average and, as is typical of RA, three-quarters were women. RA ...
- Gene Modifying Immunotherapy for Blood Cancer Market to Expand on Account of Rising Research and Development Activities By 2027 on November 13, 2019 at 2:36 am
Research Nester released a report titled “Gene Modifying Immunotherapy for Blood Cancer Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global gene ...
- Regular screening, immunotherapy among latest weapons against lung cancer on November 12, 2019 at 2:00 pm
The chances of remission and recovery decline in later stage cancer, making the low-dose CT scan even more important. * I understand and agree that registration on or use of this site constitutes ...
via Bing News